The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal ...
A company claiming to be “America’s Largest Ophthalmic Pharmacy” has issued a recall for multiple eye drop products for the ...
You know the drill by now. You're sitting in the purgatory of the service center waiting room. Precisely 63 minutes into your wait, the service adviser walks out with a clipboard and calls your name — ...
K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines. Inflammasome Therapeutics has completed enrollment in a multicenter, dose-ranging phase 2 trial (NCT06164587) for its ...
K8, a dual inflammasome inhibitor, is being tested for geographic atrophy in a phase 2 trial involving 30 patients across 9 US centers. Kamuvudines, derived from anti-HIV drugs, retain ...
Forbes contributors publish independent expert analyses and insights. AI researcher working with the UN and others to drive social change. Dec 01, 2025, 07:08am EST Hacker. A man in a hoodie with a ...
NEWTON, Mass.--(BUSINESS WIRE)--#NRTIs--Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and ...
Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy Inflammasome Therapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback